How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?

ABSTRACT: Despite an increasing desire to use historical cohorts as "synthetic" controls for new drug evaluation, limited data exist regarding the comparability of real-world outcomes to those in clinical trials. Governmental cancer data often lacks details on treatment, response, and molecular characterization of disease sub-groups. The Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry (ALLG NBCR) includes source information on morphology, cytogenetics, flow cytometry, and molecular features linked to treatment received (including transplantation), response to treatment, relapse, and survival outcome. Using data from 942 AML patients enrolled between 2012-2018, we assessed age and disease-matched control and interventional populations from published randomized trials that led

SUBMITTER: Tiong IS 

PROVIDER: S-EPMC10965987 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature